FIRST RESULTS FROM SUNRISE-1 IN PATIENTS WITH BCG UNRESPONSIVE HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER RECEIVING TAR-200 IN COMBINATION WITH CETRELIMAB, TAR-200, OR CETRELIMAB ALONE

被引：0
|
作者：
Daneshmand, Siamak
van der Heijden, Michiel S.
Jacob, Joseph M.
Necchi, Andrea
Xylinas, Evanguelos
Morris, David S.
Spiegelhalder, Philip
Zainfeld, Daniel
Kang, Taek Won
Matulay, Justin T.
Belkoff, Laurence H.
Decaestecker, Karel
Arentsen, Harm
Hampras, Shalaka
Jin, Shu
Cutie, Christopher J.
Sweiti, Hussein
Stromberg, Katherine
Martin, Jason
Simone, Giuseppe
机构：
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
LBA02-03
引用
收藏
页码：E1187 / E1187
页数：1
相关论文
共 50 条
  • [31] Updated Interim Analysis from Keynote-057: Pembrolizumab Monotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
    Krieger, Laurence
    de Wit, Ronald
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Balar, Arjun Vasant
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 52 - 53
  • [32] FIRST SAFETY AND EFFICACY RESULTS OF THE TAR-210 ERDAFITINIB INTRAVESICAL DELIVERY SYSTEM IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER WITH SELECT FGFR ALTERATIONS
    Vilaseca, Antoni
    Jayram, Gautam
    Raventos, Carles
    Shore, Neal D.
    Zainfeld, Daniel
    Kang, Taek Won
    Ku, Ja Hyeon
    Meeks, Joshua
    Rodriguez Faba, Oscar
    Roghmann, Florian
    Daneshmand, Siamak
    Beeharry, Neil
    Cost, Carrye R.
    Kalota, Anna
    Lauring, Josh
    Peterson, Michelle R.
    Quiroz, Michelle
    Stone, Nicole L.
    Zhu, Wei
    Gurrero Ramos, Felix
    JOURNAL OF UROLOGY, 2024, 211 (05): : E987 - E988
  • [33] Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
    Li, Zhiyong
    He, Liru
    Li, Xiangdong
    Yao, Kai
    Liu, Yang
    Qin, Zike
    Ye, Yunlin
    Zhou, Fangjian
    Liu, Zhuowei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [34] First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non-muscle-invasive bladder cancer with select FGFR alterations
    Vilaseca, A.
    Jayram, G.
    Raventos, C.
    Shore, N. D.
    Zainfeld, D.
    Kang, T. W.
    Ku, J. H.
    Meeks, J.
    Rodriguez Faba, O.
    Roghmann, F.
    Daneshmand, S.
    Beeharry, N.
    Cost, C. R.
    Kalota, A.
    Lauring, J.
    Peterson, M. R.
    Quiroz, M. Q.
    Stone, N. L.
    Zhu, W.
    Gurrero-Ramos, F.
    EUROPEAN UROLOGY, 2024, 85 : S1506 - S1507
  • [35] Interim results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
    Li, Zhiyong
    He, Liru
    Yao, Kai
    Ye, Yunlin
    Li, Xiangdong
    Qin, Zike
    Han, Hui
    Zhou, Fangjian
    Liu, Zhuowei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists
    Moussa, Mohamad
    Chakra, Mohamad Abou
    Shore, Neal D.
    Papatsoris, Athanasios
    Farahat, Yasser
    ODonnell, Michael A.
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2024, 96 (01)
  • [37] Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer
    Tomas Thiel
    Charlotta Ryk
    Lotta Renström-Koskela
    Gunnar Steineck
    Martin C. Schumacher
    N. Peter Wiklund
    Petra J. de Verdier
    World Journal of Urology, 2019, 37 : 155 - 163
  • [38] Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer
    Thiel, Tomas
    Ryk, Charlotta
    Renstrom-Koskela, Lotta
    Steineck, Gunnar
    Schumacher, Martin C.
    Wiklund, N. Peter
    de Verdier, Petra J.
    WORLD JOURNAL OF UROLOGY, 2019, 37 (01) : 155 - 163
  • [39] COVID-19 infection threat in patients with high-risk non-muscle invasive bladder cancer receiving intravesical BCG therapy
    Akan, Serkan
    Ediz, Caner
    Kizilkan, Yunus Emre
    Alcin, Adem
    Tavukcu, Hasan Huseyin
    Yilmaz, Omer
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (03)
  • [40] Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG
    Zachos, Ioannis
    Tzortzis, Vasileios
    Mitrakas, Lampros
    Samarinas, Michael
    Karatzas, Anastasios
    Gravas, Stavros
    Vandoros, Gerasimos P.
    Melekos, Michael D.
    Papavassiliou, Athanasios G.
    TUMOR BIOLOGY, 2014, 35 (05) : 4185 - 4189
12345